Osteostep, Incorporated
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 10, 2027The maintenance fee for Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions (US 9,180,116) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions (US 11,884,624) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions (US 10,556,862) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,180,116 | Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 9,440,919 | Difluorolactam Compositions for EP4-MEDIATED Osteo Related Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 9,487,478 | Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 9,701,630 | Difluorolactam Compositions for EP4-MEDIATED Osteo Related Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 10,556,862 | Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 11,066,361 | Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 11,884,624 | Difluorolactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 9,676,712 | Lactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 9,688,627 | Lactam Compounds as EP4 Receptor-Selective Agonists for Use in the Treatment of EP4-MEDIATED Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 10,729,810 | Methods, Systems, and Compositions for Promoting Bone Growth In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.